ArticlePakistan journal of medical sciences2026
Changes in MELD-Na & Fibroscan Scores in Patients with Chronic Hepatitis-B on Entecavir: A Cohort Analysis.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine on-treatment changes in MELD-Na & Fibroscan scores after a period of six months in patients with chronic Hepatitis-B who are treated with Entecavir (ETV). Methodology: This observational cohort was conducted at Department of Medicine/Gastroenterology, Dow Medical College affiliated with Dow University of Health Sciences, Karachi, Pakistan during the period of August 2019 to December 2024. Patients of either gender aged between 18 - 80 years attending hepatitis clinic and who are on treatment for Hepatitis-B with Entecavir were inducted after informed consent. MELD-Na & Fibroscan scores were recorded at induction and after six months of treatment with ETV. Results: A total of 288 patients were enrolled including 153 (53.1%) were males with mean age of 37.6 ±11.6 years and 135 (46.9%) were females with mean age of 43.5 ±9.6 years. The difference in age between genders was significant ( Conclusion: Significant improvement in MELD-Na & Fibroscan scores were observed in patients on treatment with ETV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.